arrow
O

O. Malard

chu de nantes
H指数:36
被引数:5,482

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quality of surgical reporting and adequacy of surgical treatment in salivary gland cancer: a quality assurance ancillary study of the GORTEC 2016-02 SANTAL trial

唾液腺癌手术报告质量和手术治疗充分性:GORTEC 2016-02 SANTAL试验的质量保证辅助研究

EJSO
IF2.9
2026-08-010
PRE
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial

纳武利尤单抗联合顺铂和放疗与顺铂和放疗单药治疗术后复发高风险头颈部鳞状细胞癌患者的比较(GORTEC 2018-01 NIVOPOST-OP):一项随机、开放标签、III期试验

2025-12-220
PRE
Survival rates and prognostic factors of 118 sinonasal sarcomas among adolescents and adults: a national database REFCOR study

118例青少年及成人鼻窦肉瘤的生存率及预后因素:一项国家数据库REFCOR研究

2025-06-210
PRE
Malignant salivary gland tumors of the tongue: A multicenter REFCOR study
2024-09-200
PRE
Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial

Immunoscore-IC预测头颈鳞状细胞癌挽救性手术后辅助治疗中使用nivolumab的疗效:ADJORL1试验

2024-09-010
PRE
Carcinomas of the external auditory canal: Management and results: A multicenter REFCOR propensity score matching study
2024-04-010
OA
The Prognostic Value of Olfactory Dysfunction in Patients with COVID-19: The COVIDORA Study
2024-02-220
OAAI
Functional or radical surgical treatment of laryngeal chondrosarcoma, analysis of survival and prognostic factors: A REFCOR and NetSarc-ResOs multicenter study of 74 cases
EJSO
IF2.9
2024-02-013
PRE
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity
2023-12-182
OAAI
Management of 80 sinonasal undifferentiated carcinomas. Retrospective multicentre study of the French Network of Rare Head and Neck Cancers (REFCOR)

80例鼻窦未分化癌的治疗。法国罕见头颈癌网络 (REFCOR) 的回顾性多中心研究

EJSO
IF2.9
2023-12-012
OAAI
Survival outcomes, prognostic factors, and effect of adjuvant radiotherapy and prophylactic neck dissection in salivary acinic cell carcinoma: A prospective multicenter REFCOR study of 187 patients
2023-05-014
PRE